NCT05821556 2026-04-14
Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients
National Cancer Institute, Naples
Phase 2 Recruiting
Clinical Trials
26 trialsNCT03907475 2026-04-13
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06790602 2026-04-09
SWITCH
University of California, San Diego
Phase 2 Recruiting
NCT05999994 2026-03-27
CAMPFIRE
Eli Lilly and Company
Phase 2 Recruiting
NCT03498521 2025-11-19
CUPISCO
Hoffmann-La Roche
Phase 2 Completed
NCT05673811 2025-04-16
VIRAGE
Theriva Biologics SL
Phase 2 Completed
NCT06696742 2024-11-20
PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT02607202 2024-01-26
AGNOSTOS
Fondazione del Piemonte per l'Oncologia
Phase 2 Completed
NCT02412670 2023-07-10
Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT02487277 2020-01-02
PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma
University of California, San Francisco
Phase 2 Terminated
NCT01376310 2019-02-19
GSK1120212 Rollover Study
Novartis
Phase 2 Terminated
NCT02195180 2018-07-27
Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic Carcinoma
ERYtech Pharma
Phase 2 Completed
NCT02241551 2018-07-26
Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer
University of Pittsburgh
Phase 2 Terminated
NCT00066781 2017-04-04
Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT02590055 2015-10-28
Phase 2 Study of Gemcitabine and Docetaxel Combination Chemotherapy in Patients With Carcinoma of Unknown Primary
Samsung Medical Center
Phase 2 Unknown
NCT00119314 2015-05-27
Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin
Rutgers, The State University of New Jersey
Phase 2 Withdrawn
NCT00458315 2015-05-08
Cisplatin/Paclitaxel/Gemcitabine +/- Avastin in Patients With Unknown Primary Tumor
Rigshospitalet, Denmark
Phase 2 Withdrawn
NCT00998322 2015-04-10
A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma
Oncolytics Biotech
Phase 2 Completed
NCT01124786 2014-04-17
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)
Clovis Oncology, Inc.
Phase 2 Completed
NCT00661830 2013-11-21
Gemcitabine and Sorafenib in Advanced Biliary Tract Cancer (GEMSO)
Johannes Gutenberg University Mainz
Phase 2 Completed
NCT01231581 2013-09-26
Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer
GlaxoSmithKline
Phase 2 Completed
NCT01830322 2013-08-14
Safety and Effectiveness Study of CPI-613 and/or Gemcitabine to Treat Metastatic Pancreatic Cancer
Cornerstone Pharmaceuticals
Phase 2 Withdrawn
NCT00353145 2012-08-02
Gemox as First and Second Line Therapy in Unknown Primary Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01216345 2010-10-07
Cetuximab + Gemox in Biliary Tract Cancer
Association of Research on the Biology of Liver Tumors
Phase 2 Completed
NCT00148135 2008-01-10
Combination of Carboplatin, Gemcitabine, and Capecitabine in Patients With Carcinoma of Unknown Primary Site
University of Michigan Rogel Cancer Center
Phase 2 Terminated
NCT00191503 2007-01-26
Gemcitabine and Pemetrexed in Primary Unknown Adenocarcinoma
Eli Lilly and Company
Phase 2 Completed